Report

src

Global Pulmonary Arterial Hypertension (PAH) Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Endothelin Receptor Antagonists, SGC Stimulators, PDE-5 Inhibitors, Prostacyclin & Prostacyclin Analogs and Others), By Route of Administration (Oral, Intravenous/Subcutaneous and Others), By Type (Innovative and Generics), By Distribution Channel (Hospitals, Retail Pharmacies and Online Pharmacies), and Regional Forecasts, 2023-2030

Customization
  • We provide customized solutions to cater to your specific requirement services any region, product, or any specific market segment.
The global pulmonary arterial hypertension (PAH) market size was valued at USD 7.5 billion in 2022. The market is projected to grow from USD 7.5 billion in 2022 to USD 10.9 billion by 2030, exhibiting a CAGR of 5.50% during the forecast period.
 
In the upcoming years, the pulmonary arterial hypertension (PAH) market will expand due to the rising occurrences of cardiovascular and pulmonary illnesses and the aging population, which is prone to such medical conditions. Furthermore, the risks of hypertension and high blood pressure have increased due to changes in lifestyle, such as a lack of physical activity, excessive alcohol consumption, and bad eating habits. The market for pulmonary arterial hypertension (PAH) is expanding as a result of factors like this, the creation of novel orphan drugs and technologically advanced devices for the treatment of PAH, the growing public awareness of the readily available treatment options for PAH, and an innovative healthcare system.
 
COVID-19 IMPACT

Since the COVID-19 pandemic has had such a profound influence on nearly every business, its impacts are anticipated to have an adverse effect on that industry's growth throughout the projected period. Several shifts in consumer demand and behavior, purchasing patterns, supply chain rerouting, and substantial government activities have been observed globally. The COVID-19 epidemic has benefited the market for pulmonary arterial hypertension due to increased COVID-19 infections among patients who already have pulmonary artery hypertension. Significantly impacted by COVID-19 are the identification and management of pulmonary hypertension and the discovery of an increased mortality risk in patients with pulmonary artery hypertension.
 
DRIVING FACTORS

Growing Prevalence of Pulmonary Arterial Hypertension to Drive Market Growth

The market for pulmonary arterial hypertension is expanding as pulmonary arterial hypertension (PAH) condition is becoming more common. During the projected period, it is anticipated that the growing prevalence of PAH disorders and the associated hospitalization of patients for treatment will increase demand for pertinent medications. According to research by the National Organization for Rare Disorders, Inc., there are 500–1000 new cases of PAH in the United States annually or 1–2 cases per million people, and comparable incidence rates are anticipated in Europe.
 
RESTRAINING FACTORS

Side-Effects Associated with PAH to Limit Market Growth

The growth of the global market is projected to be hampered by side effects related to PAH medications. Vasodilators are typically recommended to treat PAH patients to widen and unblock clogged blood arteries. Studies show that vasodilators are associated with various adverse effects, such as edoema, heart palpitations, tachycardia, and chest pain. The U.S. Food and Drug Administration (USFDA) controls the use of this medication due to the significant negative effects associated with its usage in chronically ill patients. Additionally, producers of PAH medications that lower blood pressure and widen blood arteries must provide reasonable assurance regarding the security and efficiency of their products. Before going on sale, these medications need FDA approval in the United States.
 
SEGMENTATION

By Drug Class

Pulmonary Arterial Hypertension (PAH) Market By drug Glass
Based on drug class, the pulmonary arterial hypertension (PAH) market is segmented into endothelin receptor antagonists, SGC stimulators, PDE-5 inhibitors, prostacyclin & prostacyclin analogs and others. The prostacyclin & prostacyclin analogs categories dominated the market in 2022. High demand and expanding indications are two important elements that significantly impact the huge share. Uptravi, a product in the Prostacyclin and Prostacyclin Analogs category, was given FDA approval in July 2021 for intravenous use in people with pulmonary arterial hypertension. The SGC simulator market is anticipated to expand at a CAGR of more than 5%. By amplifying NO-sGC signaling, sGC stimulators can ensure that sGC is activated to its fullest potential. The sole medication in this class licensed for PAH is riciguat (Adempas from Bayer). Sales of Adempas increased by almost 50% in 2020 over 2019, showing strong demand.
 
By Route of Administration

Based on the route of administration, the pulmonary arterial hypertension (PAH) market is segmented into oral, intravenous/subscutaneous and others. The oral category dominated the market in 2022. This is because patients prefer the oral method of administration, and oral formulations for pulmonary arterial hypertension are becoming more widely available. Oral PAH medications include Letairis, Opsumit, Adcirca, and Revatio, to name a few. For instance, sales of Johnson & Johnson's Opsumit tablets were USD 1.6 billion in 2020. Compared to 2019, the sales reflected a year-over-year gain of 23.5%. Other reasons influencing the adoption of oral medication administration include patient safety, affordability, high efficacy, and quick drug delivery.
 
By Type

Based on type, the pulmonary arterial hypertension (PAH) market is segmented into innovative and generics. The innovative category dominated the market in 2022. Key patents expiring, more generic drugs being released, expanding demand in emerging regions, and initiatives by large firms are all significant reasons for the growth. For instance, Zydus Healthcare Limited gained FDA approval in April 2021 to market a generic version of Opsumit Macitentan Tablets.
 
By Distribution Channel

Based on distribution channels, the pulmonary arterial hypertension (PAH) market is segmented into hospitals, retail pharmacies and online pharmacies. The hospital category dominated the market in 2022. Hospital pharmacies work tirelessly to uphold the highest standards of pharmaceutical care and medication administration for patients. In this line of work, pharmacists administer medicines, do quality checks, generate and revise dosage forms, monitor, report drug safety, and create medication budgets.
 
REGIONAL INSIGHTS

Pulmonary Arterial Hypertension (PAH) Market By Region 
North America is projected to hold the largest share of the pulmonary arterial hypertension (PAH) market over the forecast period. The sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments, are to blame for a significant portion. Additionally, heightened awareness, a high number of diagnoses, and favorable government measures boost the expansion of the industry in this area. The presence of important businesses and a well-planned reimbursement mechanism support the local market expansion. On the other hand, the Asia Pacific pulmonary arterial hypertension (PAH) market is anticipated to grow significantly. This is because generic drug use is increasing, important pharmaceutical businesses are nearby, and the healthcare system is evolving. This improved the company's portfolio. The area's need for better healthcare services is also driven by the region's enormous population base and the expanding burden of diseases like HIV that cause PAH.
 
LIST OF KEY COMPANIES PROFILED:
  • United Therapeutics Corporation
  • Bayer; Gilead Sciences, Inc.
  • Johnson & Johnson
  • Viatris Inc.
  • GlaxoSmithKline
  • Sandoz Inc. (Novartis)
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceuticals Inc.
Recent Development:
  • February 2022: The first "digital hub" in Saudi Arabia was established by German company Bayer to help treat pulmonary hypertension (PH). During the COVID-19 pandemic, the AAN Digital Hub fills in gaps in disease diagnosis and treatment. They simplify patient referrals online and facilitate knowledge sharing between general practitioners, specialists, and their patients.
  • May 2019: Teva Pharmaceutical Industries Ltd. introduced a generic version of Gilead's Letairis (ambrisentan) tablets in the United States. An endothelin receptor antagonist called ambrisentan is prescribed to treat pulmonary arterial hypertension (PAH).
REPORT SCOPE AND SEGMENTATION
 
Attributes Details
Market Size in 2022 USD 7.5 Billion
Market Forecast in 2030 USD 10.9 Billion
Compound Annual Growth Rate 5.50%
Unit Revenue (USD Million) and Volume (Kilo Tons)
Segmentation By Drug Class, By Route of Administration, By Type, By Distribution Channel and By Geography
By Drug Class
  • Endothelin Receptor Antagonists
  • SGC Stimulators
  • PDE-5 Inhibitors
  • Prostacyclin & Prostacyclin Analogs
  • Others
By Route of Administration
  • Oral
  • Intravenous/ Subscutaneous
  • Others
By Type
  • Innovative
  • Generics
By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
By Region
  • North America: U.S and Canada
  • Europe: Germany, Italy, Russia, U.K, Spain, France, Rest of Europe
  • APAC: China, Australia, Japan, India, South Korea, South East Asia, Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Chile
  • The Middle East And Africa: South Africa, GCC, Rest of MEA
Base Year 2022
Historical Year 2016-2021
Forecast Year 2023-2030
Chapter 1    Preface

    1.1    Report Scope and Description
        1.1.1    Study Purpose
        1.1.2    Target Audience
        1.1.3    USP and Key Offerings
    1.2    Key Benefits for Stakeholders
    1.3    Report Scope

Chapter 2    Report Summary

    2.1    Key Findings
        2.1.1    Top Investment Pockets
    2.2    Market Snapshot: Global Pulmonary Arterial Hypertension (PAH) Market
    2.3    Global Pulmonary Arterial Hypertension (PAH) Market, 2018 – 2028 (US$ Mn)

Chapter 3    COVID 19 Impact Analysis

    3.1    Impact Assessment of COVID-19 Pandemic, By Region
        3.1.1    North America: Impact of COVID-19 Pandemic
        3.1.2    Europe: Impact of COVID-19 Pandemic
        3.1.3    Asia pacific: Impact of COVID-19 Pandemic
        3.1.4    Latin America: Impact of COVID-19 Pandemic
        3.1.5    Middle-East and Africa: Impact of COVID-19 Pandemic
    3.2    Key Strategies Undertaken by Companies to Tackle COVID-19
    3.3    Quarterly Market Revenue by Region 2021 & 2022
    3.4    Pre COVID-19 Market Revenue, By Region, 2016-2019        (USD Million)
    3.5    Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    3.6    Short Term Dynamics
    3.7    Long Term Dynamics

Chapter 4    Global Pulmonary Arterial Hypertension (PAH) Market, By Drug Class Segment Analysis

    4.1    Pulmonary Arterial Hypertension (PAH) Market Overview, By Drug Class Segment
        4.1.1    Global Pulmonary Arterial Hypertension (PAH) Market Revenue Share, By Drug Class, 2022 & 2028 (Value, %)
    4.2    Endothelin Receptor Antagonists
        4.2.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        4.2.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.2.3    Key Market Trends, Growth Factors, & Opportunities
    4.3    SGC Stimulators
        4.3.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        4.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.3.3    Key Market Trends, Growth Factors, & Opportunities
    4.4    PDE-5 Inhibitors
        4.4.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        4.4.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.4.3    Key Market Trends, Growth Factors, & Opportunities
    4.5    Prostacyclin & Prostacyclin Analogs
        4.5.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        4.5.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.5.3    Key Market Trends, Growth Factors, & Opportunities
    4.6    Others
        4.6.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        4.6.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.6.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 5    Global Pulmonary Arterial Hypertension (PAH) Market, By Route of Administration Segment Analysis

    5.1    Pulmonary Arterial Hypertension (PAH) Market Overview, By Route of Administration Segment
        5.1.1    Global Pulmonary Arterial Hypertension (PAH) Market Revenue Share, By Route of Administration, 2022 & 2028 (Value, %)
    5.2    Oral
        5.2.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        5.2.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.2.3    Key Market Trends, Growth Factors, & Opportunities
    5.3    Intravenous/ Subscutaneous
        5.3.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        5.3.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.3.3    Key Market Trends, Growth Factors, & Opportunities
    5.4    Others
        5.4.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        5.4.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.4.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 6    Global Pulmonary Arterial Hypertension (PAH) Market, By Type Segment Analysis

    6.1    Pulmonary Arterial Hypertension (PAH) Market Overview, By Type Segment
        6.1.1    Global Pulmonary Arterial Hypertension (PAH) Market Value Share, By Type, 2021 & 2028 (Value, %)
    6.2    Innovative
        6.2.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        6.2.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        6.2.3    Key Market Trends, Growth Factors, & Opportunities
    6.3    Generics
        6.3.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        6.3.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        6.3.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 7    Global Pulmonary Arterial Hypertension (PAH) Market, By Distribution Channel Segment Analysis

    7.1    Pulmonary Arterial Hypertension (PAH) Market Overview, By Distribution Channel Segment
        7.1.1    Global Pulmonary Arterial Hypertension (PAH) Market Revenue Share, By Distribution Channel, 2022 & 2028 (Value, %)
    7.2    Hospitals
        7.2.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        7.2.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.2.3    Key Market Trends, Growth Factors, & Opportunities
    7.3    Retail Pharmacies
        7.3.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        7.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.3.3    Key Market Trends, Growth Factors, & Opportunities
    7.4    Online Pharmacies
        7.4.1    Pulmonary Arterial Hypertension (PAH) Share Forecast, By Region (USD Million)
        7.4.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.4.3    Key Market Trends, Growth Factors, & Opportunities
            
Chapter 8    Pulmonary Arterial Hypertension (PAH) Market – Regional Analysis, 2022 – 2028

    8.1    Pulmonary Arterial Hypertension (PAH) market Overview, by Region Segment
        8.1.1    Global Pulmonary Arterial Hypertension (PAH) market Revenue Share, By Region, 2022 & 2028
        8.1.2    Global Pulmonary Arterial Hypertension (PAH) Market Revenue, By Region, 2017 – 2028 (US$ Mn)
        8.1.3    Global Pulmonary Arterial Hypertension (PAH) market Revenue, By Drug Class, 2017 – 2028 (US$ Mn)
        8.1.4    Global Pulmonary Arterial Hypertension (PAH) market Revenue, By Route of Administration, 2017 – 2028 (US$ Mn)
        8.1.5    Global Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2017 – 2028 (US$ Mn)
        8.1.6    Global Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2017 – 2028 (US$ Mn)
    8.2    North America
        8.2.1    North America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        8.2.2    North America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.2.3    North America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.2.4    North America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.2.5    North America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.2.6    U.S. Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.2.7    Canada Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.2.8    Mexico Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    8.3    Europe
        8.3.1    Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        8.3.2    Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.3.3    Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.3.4    Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.3.5    Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.3.6    Germany Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.3.7    France Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.3.8    U.K. Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.3.9    Italy Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.3.10    Spain Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.3.11    Rest of Europe Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    8.4    Asia Pacific
        8.4.1    Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        8.4.2    Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.4.3    Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.4.4    Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.4.5    Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.4.6    China Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.4.7    Japan Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.4.8    India Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.4.9    South Korea Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.4.10    South-East Asia Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.4.11    Rest of Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    8.5    Latin America
        8.5.1    Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        8.5.2    Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.5.3    Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.5.4    Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.5.5    Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.5.6    Brazil Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.5.7    Argentina Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.5.8    Rest of Latin America Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    8.6    The Middle-East and Africa
        8.6.1    The Middle-East and Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        8.6.2    The Middle-East and Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.6.3    The Middle-East and Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.6.4    The Middle-East and Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.6.5    The Middle-East and Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        8.6.6    GCC Countries Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.6.7    South Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        8.6.8    Rest of Middle-East Africa Pulmonary Arterial Hypertension (PAH) Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)

Chapter 9    Pulmonary Arterial Hypertension (PAH) Market – Industry Analysis

    9.1    Introduction
    9.2    Market Drivers
        9.2.1    Driving Factor 1 Analysis
        9.2.2    Driving Factor 2 Analysis
    9.3    Market Restraints
        9.3.1    Restraining Factor Analysis
    9.4    Market Opportunities
        9.4.1    Market Opportunity Analysis
    9.5    Porter’s Five Forces Analysis
    9.6    PEST Analysis
    9.7    Regulatory Landscape
    9.8    Technology Landscape
    9.9      Value Chain Analysis

Chapter 10    Competitive Landscape

    10.1    Company Market Share Analysis – 2022
        10.1.1    Global Pulmonary Arterial Hypertension (PAH) market: Company Market Share, 2022
        10.1.2    Global Pulmonary Arterial Hypertension (PAH) Market: Company Market Share, 2022
    10.2    Strategic Developments
        10.2.1    Acquisitions & Mergers
        10.2.2    New Product Launch
        10.2.3    Regional Expansion
    10.3    Company Strategic Developments – Heat Map Analysis

Chapter 11    Company Profiles

    11.1    United Therapeutics Corporation
        11.1.1    Company Overview
        11.1.2    Key Executives
        11.1.3    Product Portfolio
        11.1.4    Financial Overview
        11.1.5    Operating Business Segments
        11.1.6    Business Segment Performance
        11.1.7    Recent Developments
    11.2    Bayer; Gilead Sciences, Inc.
    11.3    Johnson & Johnson
    11.4    Viatris Inc.
    11.5    GlaxoSmithKline
    11.6    Sandoz Inc. (Novartis)
    11.7    Lupin Pharmaceuticals, Inc.
    11.8    Sun Pharmaceutical Industries, Inc.
    11.9    Teva Pharmaceuticals Inc.

Chapter 12    Research Methodology

    12.1    Research Methodology
    12.2    Phase I – Secondary Research
    12.3    Phase II - Data Modeling
        12.3.1    Company Share Analysis Model
        12.3.2    Revenue Based Modelling
    12.4    Phase III – Primary Research
    12.5    Research Limitations
        12.5.1    Assumptions
No Methodology
No Available